Ten of 16 patients with large B cell lymphoma with progressive disease after CAR19 treatment had absent or low CD19.
6445212 RF5BSW5T items 1 apa default asc 1
Spiegel, J. Y., Patel, S., Muffly, L., Hossain, N. M., Oak, J., Baird, J. H., Frank, M. J., Shiraz, P., Sahaf, B., Craig, J., Iglesias, M., Younes, S., Natkunam, Y., Ozawa, M. G., Yang, E., Tamaresis, J., Chinnasamy, H., Ehlinger, Z., Reynolds, W., … Miklos, D. B. (2021). CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nature Medicine, 1–13. https://doi.org/10.1038/s41591-021-01436-0 Cite
Investigators found that high CD14+ cell content posed a challenge for manufacturing CAR T cells especially in patients with non-Hodgkin’s lymphoma and multiple myeloma due to the non-specific phagocytosis of the magnetic beads used to activate CD3+ T cells.
[Molecular Therapy-Methods & Clinical Development]
6445212 SNW97FRU items 1 apa default asc 1
Wang, X., Borquez-Ojeda, O., Stefanski, J., Du, F., Qu, J., Chaudhari, J., Thummar, K., Zhu, M., Shen, L., Hall, M., Gautam, P., Wang, Y., Senechal, B., Sikder, D., Adusumilli, P. S., Brentjens, R. J., Curran, K., Geyer, M. B., Mailankhody, S., … Rivière, I. (2021). Depletion of High-Content CD14+ Cells from Apheresis Products is Critical for the Successful Transduction and Expansion of CAR T cells during Large-scale cGMP Manufacturing. Molecular Therapy - Methods & Clinical Development, 0(0). https://doi.org/10.1016/j.omtm.2021.06.014 Cite
In this open-label, single-arm Phase I/II trial, 87 patients with recurrent/refractory non-Hodgkin lymphoma received an infusion at doses of 0.5 × 106–8 × 106 TanCAR7 T cells per kilogram of body weight after conditioning chemotherapy.
6445218 PTLWYCDY items 1 apa default asc 1
Researchers provided in-depth investigation of copy number alteration heterogeneity in phenotypically characterized circulating tumor cells at resistance to Anaplastic Lymphoma Kinase (ALK)-tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer.
[npj Precision Oncology]
6445212 44S6796E items 1 apa default asc 1
Investigators mapped the cleavage site to Asn654-Leu655 and demonstrated that cleavage inhibition of wild-type anaplastic lymphoma kinase significantly impeded neuroblastoma cell migration with subsequent prolongation of survival in mouse models.
6445212 NV4IIMRM items 1 apa default asc 1
Untreated older acute myeloid leukemia (AML) patients were randomized to cytarabine and daunorubicin followed by cytarabine consolidation with or without G3139. Addition of G3139 to chemotherapy failed to improve outcomes of older AML patients.
7992332 34GLIPEP items 1 apa default asc 1
Scientists showed that the bromodomain-containing protein 4 (BRD4) inhibitor JQ1 promoted the apoptosis of B16 melanoma cells by altering mitochondrial dynamics, thereby inducing mitochondrial dysfunction and increasing oxidative stress.
6445212 88Z5FRPV items 1 apa default asc 1
To identify and interrogate malignant clones in matched skin and blood from leukemic MF and SS patients, we combine T cell receptor clonotyping, with quantification of gene expression and cell surface markers at the single cell level.
6445218 Y696KVFU items 1 apa default asc 1
Herrera, A., Cheng, A., Mimitou, E. P., Seffens, A., George, D. D., Bar-Natan, M., Heguy, A., Ruggles, K. V., Scher, J. U., Hymes, K., Latkowski, J.-A., Odum, N., Kadin, M. E., Ouyang, Z., Geskin, L., Smibert, P., Buus, T. B., & Koralov, S. (2021). Multimodal single-cell analysis of cutaneous T cell lymphoma reveals distinct sub-clonal tissue-dependent signatures. Blood, blood.2020009346. https://doi.org/10.1182/blood.2020009346 Cite
The authors revealed a frequent activation of RelB in a large cohort of diffuse large B-cell lymphoma patients and cell lines, independently of their ABC or GCB subtypes.
6445218 7TUWDALM items 1 apa default asc 1
Eluard, B., Nuan-Aliman, S., Faumont, N., Collares, D., Bordereaux, D., Montagne, A., Martins, I., Cagnard, N., Caly, M., Taoui, O., Lordello, L., Lehmann-Che, J., Tesson, B., Martinez-Climent, J.-A. A., Copie-Bergman, C., Haioun, C., Tilly, H., Bonsang, B., Vincent-Salomon, A., … Baud, V. I. (2021). The alternative RelB NF-κB subunit is a novel critical player in diffuse large B-cell lymphoma. Blood, blood.2020010039. https://doi.org/10.1182/blood.2020010039 Cite
Scientists screened a total of 521 tumor specimens from Chinese patients with lung cancer for anaplastic lymphoma receptor tyrosine kinase fusion by immunohistochemistry and confirmed by fluorescence in situ hybridization.
7753456 I2JP385T items 1 apa default asc 1
Foundation Medicine, Inc. announced that it has received approval from the US FDA for FoundationOne®CDx to be used as a companion diagnostic for ALUNBRIG®, which is currently FDA-approved for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer as detected by an FDA-approved test.
[Foundation Medicine, Inc.]
7753456 nan items 1 apa default asc 1